JSKN003 Combined Treatment of HER2-positive Gastric Cancer
This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.
HER2-positive Gastric Cancer
DRUG: JSKN003|DRUG: KN026|DRUG: Capecitabine|DRUG: Enlonstobart|DRUG: Oxaliplatin|DRUG: Trastuzumab|DRUG: Pembolizumab
Objective Response Rate (ORR) of the first-line population, Frame: Up to approximately 5 years|Incidence and severity of TEAE and SAE of the first-line population, Up to approximately 5 years|pCR rate after neoadjuvant therapy of perioperative population, Up to approximately 5 years
Disease Control Rate (DCR) of the first-line population, Up to approximately 5 years|Duration of Response (DoR) of the first-line population, Up to approximately 5 years|Progression-free survival (PFS) of the first-line populations, Up to approximately 5 years|Major pathological response (MPR) rate of perioperative population, Up to approximately 5 years|R0 rate of perioperative population, Up to approximately 5 years|Event-free survival (EFS) of perioperative population, Up to approximately 5 years|Overall Survival (OS), Up to approximately 5 years|Incidence and severity of AE, Up to approximately 5 years|Blood concentration of JSKN003, Up to approximately 2 years|Blood concentration of total antibodies for JSKN003, Up to approximately 2 years|Blood concentration of free toxins for JSKN003, Up to approximately 2 years|Serum concentration of KN026, Up to approximately 2 years|Serum concentration of Enlonstobart;, Up to approximately 2 years|Anti-drug antibodies (ADA) related to JSKN003, Up to approximately 2 years|Title: ADA related to KN026, Up to approximately 2 years|ADA related to Enlonstobart, Up to approximately 2 years
This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.